Key facts
- Indivi’s last known valuation is $176.2M (Nov 2025).
- It has raised $31.2M; the latest was Later Stage VC ($18.7M) in Nov 2025.
- Notable investors include Innovate UK, Ava Investors, Lichtsteiner Foundation, Zühlke Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Indivi
- ·The full record, as it builds
Funding rounds
No funding rounds for Indivi are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Indivi
Developer of digital biomarkers designed to accompany and accelerate new drug development in neuroscience. The company's biomarkers measure patient symptoms precisely and objectively, over long periods of time and collect health information, enabling researchers to improve research for new treatments in neuroscience.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2012
- Employees
- 56
- Website
- indivi.io/
- Ownership
- Privately Held (backing)
Indivi doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Indivi shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Indivi in its N-PORT filings yet. We sweep new filings monthly.